Omalizumab Updosing Allows Disease Activity Control in Refractory Patients With Chronic Spontaneous Urticaria

British Journal of Dermatology - United Kingdom
doi 10.1111/bjd.16379
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Omalizumab Treatment in Patients With Chronic Spontaneous Urticaria

Bőrgyógyászati és Venerológiai Szemle
2015English

Refractory Chronic Spontaneous Urticaria Treated With Omalizumab in an Adolescent With Common Variable Immunodeficiency

Frontiers in Immunology
AllergyImmunology
2019English

Transient Hair Loss in Patients With Chronic Spontaneous Urticaria Treated With Omalizumab

European Annals of Allergy and Clinical Immunology
AllergyImmunology
2017English

Efficacy of Omalizumab in Treatment-Resistant Chronic Spontaneous Urticaria

Asim, Allerji, Immunoloji
Respiratory MedicinePulmonaryAllergyImmunology
2018English

Treatment Refractory Chronic Spontaneous Urticaria Patients Achieves Remission With Low Molecular Weight Heparin

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

The Efficacy of Omalizumab Therapy in Chronic Spontaneous Urticaria: A Retrospective Analysis

Turkderm Deri Hastaliklari ve Frengi Arsivi
DermatologyInfectious Diseases
2019English

Omalizumab in Chronic Urticaria: A Comprehensive Review

Turkderm Deri Hastaliklari ve Frengi Arsivi
DermatologyInfectious Diseases
2018English

Strategies for Discontinuing Omalizumab in Patients With Chronic Urticaria: Real-World Findings

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Clinical Management of Urticaria Using Omalizumab: The First Licensed Biological Therapy Available for Chronic Spontaneous Urticaria

Journal of the European Academy of Dermatology and Venereology
DermatologyInfectious Diseases
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy